Next Article in Journal
Does Secondary Inflammatory Breast Cancer Represent Post-Surgical Metastatic Disease?
Next Article in Special Issue
Epithelial-Mesenchymal Transition Is a Critical Step in Tumorgenesis of Pancreatic Neuroendocrine Tumors
Previous Article in Journal / Special Issue
Primary Hepatic Gastrinoma Causing Zollinger-Ellison Syndrome: A Rare and Challenging Diagnosis
Cancers 2012, 4(1), 141-155; doi:10.3390/cancers4010141
Article

Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review

1,†
, 1,†
, 2
, 3
, 4
, 5
, 6
, 1
, 1
 and 1,*
Received: 30 December 2011; in revised form: 30 January 2012 / Accepted: 10 February 2012 / Published: 15 February 2012
(This article belongs to the Special Issue Neuroendocrine Tumors)
View Full-Text   |   Download PDF [160 KB, uploaded 15 February 2012]   |   Browse Figures
Abstract: The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrine tumors (NETs) of the GastroEnteroPancreatic-(GEP-) system depending on tumor primary location and metastatic spread. In a retrospective single-center series, sensitivities were evaluated in serum samples from 110 patients with midgut (n = 62) and pancreatic (n = 48) NETs. CgA levels were analyzed by a commercially-available immunoradiometric assay (CIS-bio) during routine follow-up in the years 2000–2009. CgA showed a higher sensitivity for midgut (68%) than pancreatic (54%) NETs. A higher CgA sensitivity and significantly higher median CgA values were found in patients with liver metastases than in those without, and in patients with hepatic and additionally extra-hepatic metastases than in those with hepatic and nodal metastases alone, respectively. We found an overall sensitivity for elevated 5HIAA excretion of 69% for midgut NETs and a significant correlation between median CgA and 5-HIAA values. The sensitivity of AP and the correlations of AP/CgA-data-pairs were low in both midgut and pancreatic NETs, although highest for metastatic pancreatic NETs. The sensitivity of CgA measurement depends on the NET primary location and spread of disease. 5-HIAA and CgA showed comparable sensitivity in midgut NETs, while AP does not seem to be useful as a tumor marker in GEP-NETs.
Keywords: neuroendocrine tumors; gastroenteropancreatic system; sensitivity; chromogranin A; CIS-bio assay; alkaline phosphatase; urinary 5-hydroxyindoleacetic acid; liver metastases neuroendocrine tumors; gastroenteropancreatic system; sensitivity; chromogranin A; CIS-bio assay; alkaline phosphatase; urinary 5-hydroxyindoleacetic acid; liver metastases
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Nölting, S.; Kuttner, A.; Lauseker, M.; Vogeser, M.; Haug, A.; Herrmann, K.A.; Hoffmann, J.N.; Spitzweg, C.; Göke, B.; Auernhammer, C.J. Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review. Cancers 2012, 4, 141-155.

AMA Style

Nölting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, Hoffmann JN, Spitzweg C, Göke B, Auernhammer CJ. Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review. Cancers. 2012; 4(1):141-155.

Chicago/Turabian Style

Nölting, Svenja; Kuttner, Axel; Lauseker, Michael; Vogeser, Michael; Haug, Alexander; Herrmann, Karin A.; Hoffmann, Johannes N.; Spitzweg, Christine; Göke, Burkhard; Auernhammer, Christoph J. 2012. "Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review." Cancers 4, no. 1: 141-155.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert